Table 1. Patient demographics . Number .... | American Society of Hematology

Table 1.

Patient demographics

	Number	%
Total	94	100
Median age (y)	67.5
Men	46	49
Women	48	51
High-risk cytogenetics∗	57	61
ECOG performance status
0	22	23
1	49	52
2	12	13
3	9	10
R-ISS stage
I	15	16
II	41	44
III	12	13
Missing	26	28
Median number of prior lines	6	6
Prior high dose melphalan with ASCT	72	77
Prior treatment
Exposure to IMiD	94	100
Exposure to proteasome inhibitor	94	100
Exposure to anti-CD38 antibody	94	100
Triple-class refractory	77	82
Penta-refractory	36	38
Exposure to BCMA therapy	18	19
CAR T therapy	12	13
BCMA-directed bispecific antibody	6	6
Belantamab mafodotin	1	1
Exposure by drug
Lenalidomide	88	94
Pomalidomide	84	89
Thalidomide	26	28
Bortezomib	91	97
Carfilzomib	82	87
Ixazomib	32	34
Daratumumab	94	100
Isatuximab	9	10
Elotuzumab	26	28
Selinexor	11	12

	Number	%
Total	94	100
Median age (y)	67.5
Men	46	49
Women	48	51
High-risk cytogenetics∗	57	61
ECOG performance status
0	22	23
1	49	52
2	12	13
3	9	10
R-ISS stage
I	15	16
II	41	44
III	12	13
Missing	26	28
Median number of prior lines	6	6
Prior high dose melphalan with ASCT	72	77
Prior treatment
Exposure to IMiD	94	100
Exposure to proteasome inhibitor	94	100
Exposure to anti-CD38 antibody	94	100
Triple-class refractory	77	82
Penta-refractory	36	38
Exposure to BCMA therapy	18	19
CAR T therapy	12	13
BCMA-directed bispecific antibody	6	6
Belantamab mafodotin	1	1
Exposure by drug
Lenalidomide	88	94
Pomalidomide	84	89
Thalidomide	26	28
Bortezomib	91	97
Carfilzomib	82	87
Ixazomib	32	34
Daratumumab	94	100
Isatuximab	9	10
Elotuzumab	26	28
Selinexor	11	12

ASCT, autologous stem cell transplant; IMiD, immunomodulatory drug.

∗

High risk cytogenetics was defined as 1 or more of the following cytogenetic aberrations: t(4;14), t(14;16), t(14;20), del 1p, del 17p, and gain/amp 1q.

View Large

This Feature Is Available To Subscribers Only